Basilea Pharmaceutica - Yet another milestone payment from Pfizer
Sales of Basilea’s antifungal drug, Cresemba (isavuconazole), in the Asia Pacific region have triggered a milestone payment of $1.25m from the company’s licence partner Pfizer, management has reported. Global Cresemba sales were $324m in FY21, resulting in significant royalty and milestone payments to Basilea. In our view, the triggering of milestones in new regions (Asia Pacific) is encouraging for Cresemba’s future sales growth. Cresemba is approved in 68 countries and marketed in 57 and is a key revenue driver for Basilea. Considerable past milestone payments from partners (Pfizer, Astellas) provide support that management is addressing a worldwide unmet medical need with Cresemba. We value Basilea Pharmaceutica at CHF847.7m or CHF71.6/share.Basilea Pharmaceutica is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of bacterial infections, fungal infections, oncology and skin diseases. Co. focuses on antibiotics and antifungals as well as oncology and dermatology drugs. Co.'s portfolio spans from innovative early-stage through clinical late-stage drug candidates to a marketed product. In the context of its international commercialization organization, Co. has subsidiaries in Denmark, France, Germany, Italy, Spain and the United Kingdom.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.